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Abstract
Background: MicroRNAs (miRNAs) are small non-coding RNAs (18–24 nucleotides) that have recently been shown to
regulate gene expression during cancer progression. Dicer, a central enzyme in the multi-component miRNA biogenesis
pathway, is involved in cutting precursor miRNAs to functionally mature forms. Emerging evidence shows that Dicer
expression is deregulated in some human malignancies and it correlates with tumor progression, yet this role has not yet
been investigated in skin cancers.
Methods and Findings: Using an anti-human monoclonal antibody against Dicer and immunohistochemistry, we compared
the expression of Dicer protein among 404 clinically annotated controls and skin tumors consisting of melanocytic nevi
(n = 71), a variety of melanomas (n = 223), carcinomas (n = 73) and sarcomas (n = 12). Results showed a cell-specific up-
regulated Dicer in 81% of cutaneous, 80% of acrolentiginous and 96% of metastatic melanoma specimens compared to
carcinoma or sarcoma specimens (P,0.0001). The expression of Dicer was significantly higher in melanomas compared to
benign melanocytic nevi (P,0.0001). In patients with cutaneous melanomas, Dicer up-regulation was found to be
significantly associated with an increased tumor mitotic index (P= 0.04), Breslow’s depth of invasion (P= 0.03), nodal
metastasis (P= 0.04) and a higher American Joint Committee on Caner (AJCC) clinical stage (P= 0.009). Using western blot
analysis, we confirmed the cell-specific up-regulation of Dicer protein in vitro. A pooled-analysis on mRNA profiling in
cutaneous tumors showed up-regulation of Dicer at the RNA level in cutaneous melanoma, also showing deregulation of
other enzymes that participate in the biogenesis and maturation of canonical miRNAs.
Conclusions: Increased Dicer expression may be a clinically useful biomarker for patients with cutaneous melanoma.
Understanding deregulation of Dicer and its influence on miRNA maturation is needed to predict the susceptibility of
melanoma patients to miRNA-based therapy in the future.
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Introduction
Small (18–24 nucleotides) non-coding RNAs, including micro-
RNAs (miRNAs), regulate gene expression in many biological
processes [1] and in human cancers [2]. miRNAs down-regulate
expression of specific target genes, in part drawing specificity from
seed sequence pairing within the 39-untranslated region of target
mRNAs leading to translational repression and/or mRNA
degradation [3]. Specific miRNAs can function as tumor
suppressor genes or oncogenes (oncomirs) [4] where deregulated
miRNA expression has been demonstrated in a variety of human
cancers including chronic lymphocytic leukemia [5], lung cancer
[6], colorectal neoplasia [7] and pancreatic endocrine and acinar
tumors [8]. Global miRNA expression profiling has provided some
evidence that the expression of certain miRNAs is deregulated
during melanoma progression. While these studies are limited to
cell lines [9,10,11] and metastatic lesions [12], little is known about
the role of miRNAs or their biogenesis pathway in clinical primary
melanoma [13,14].
Dicer, a member of the RNase III family of double-stranded
RNases, is a central enzyme in a multi-component miRNA
biogenesis pathway where the Drosha/DGCR8 complex and
Dicer act sequentially to crop long primary and precursor
miRNAs into functionally mature miRNAs [15]. The expression
levels of the processing components themselves are certainly
candidates for deregulation in the development and the progres-
sion of human cancers. For example, high dicer expression is a
poor prognostic factor in patients with prostate adenocarcinoma
[16], whereas low Dicer expression is a poor prognostic factor in
lung [17] and ovarian [18] carcinoma.
Although changes in the expression level of Dicer, and possibly
other miRNA processing enzymes, are of clinical significance in
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some cancers, these alterations or their clinical consequences in
melanoma or other skin cancers remain unknown.
We demonstrate herein that Dicer protein is specifically up-
regulated in melanoma compared to other skin cancers such as
carcinomas and sarcomas. This up-regulation is further specific to
melanoma subtype and is significantly associated with clinical
stage in patients with cutaneous melanoma. Additional analyses of
Dicer levels in tissue culture cells support a general up-regulation
of Dicer in melanoma and suggest an autonomous up-regulation
in the absence of supporting cells.
Materials and Methods
Clinical Profile of Tissue Microarrays and Cases
We used seven different tissue microarray (TMA) slides,
prepared from formalin-fixed paraffin embedded (FFPE) speci-
mens, representing a wide variety of human skin tumors, both
benign and malignant, from 404 different patients arrayed onto
slides at 80 to 100 cores per slide (in duplicates or triplicates).
This set also included complete tumor FFPE sections. The TMA
slides included normal tissue (skin and other organs), melanocytic
nevi (compound, intradermal and blue), primary melanomas
(acrolentiginous, cutaneous, desmoplastic, mucosal, ocular),
metastatic melanomas, squamous cell carcinoma, adenocarcino-
ma (eccrine, sebaceous and metastatic), basal cell carcinoma,
sarcomas (dermatofibrosarcoma protuberans and fibrosarcomas),
neurofibromas, and benign and malignant schwannomas. We
purchased TMA slides ME1001, ME801, SK803 and BC21011
from US Biomax, Inc. (Rockville, MD) and CS38-01-001 from
Cybrdi (Rockville, MD). The squamous or melanocytic differen-
tiation of tumors was confirmed by immunohistochemical
staining for cytokeratins or HMB-45, respectively, by the
manufacturers. DC-1 and DC-2 TMAs were built at Stanford
University Pathology Department (DC). For most TMAs, the
information on age, sex and anatomic sites were available. For
primary melanomas arrayed on DC-1 and DC-2 TMAs, the
information on age, tumor thickness (Breslow’s depth, Clark’s
level of invasion and histological type were available. Complete
tumor sections were also examined that included cutaneous
melanomas (n = 19), metastatic melanomas to lymph node (n = 5)
and common nevi (n = 9). At least two pathologists/dermatopa-
thologists (SSD and/or DC) confirmed all diagnoses. The
institutional review boards of the Stanford University Medical
Center and the University of Connecticut Health Center
approved this protocol.
Patients
Out of 95 patients diagnosed with primary cutaneous
melanoma, we had complete clinical follow-up information for
19 patients (mean= 26.6 month, range 7 to 64 months). The
majority of cases were obtained from the Stanford University
Pathology archive from 1997-2006. Clinical information included
gender, age, anatomic site of the primary tumor, relapse-free
survival, American Joint Committee on Cancer (AJCC) patholog-
ical (tumor, node, metastasis) stage [19], site of first metastasis,
sentinel (SLN) and non-sentinel lymph node (NSLN), distant
metastasis and overall survival. Distant metastasis was defined as
either distant nodal or visceral. Histological information included
tumor thickness (mm), Clark’s level of invasion, ulceration,
histological subtype, regression, and mitotic index (mitoses per
square millimeter) as previously described [20]. At least two
pathologists confirmed all the diagnoses of primary and metastatic
melanomas. The institutional review board of the Stanford
University Medical Center approved this protocol.
Immunohistochemistry and Statistical Analysis
Immunostaining for all cases (TMAs and complete sections) was
performed on 4-mm-thick FFPE sections mounted on charged
slides and incubated at 60uC overnight. All slides were incubated
with the anti-human Dicer monoclonal antibody through
Clonegene (1:100, clone mab 13D6, Hartford, CT), generously
provided by Dr. Henry Furneaux. We performed antigen retrieval
using DakoCytomation Target Retrieval Solution (High pH,
Catalogue No. S-3308) and biocare digital decloaking chamber
(Biocare Medical, Concord, CA) at 100uC for 10 minutes,
followed by treatment of 3% H2O2 to block the endogenous
peroxidase activity. The slides were incubated at room temper-
ature for 1 hour with anti-Dicer antibodies at 1:100 dilution.
Hematoxylin was used for counterstaining. Following the
manufacturer’s instructions, we developed the immunohistochem-
ical stain using EnVisionTM+ kit (DAKO, Carpinteria, CA).
The expression of Dicer was examined in normal skin and other
organs; Dicer immunoreactivity was seen in the cytoplasm without
nuclear staining. A semi-quantitative, four-point ordinal immuno-
reactivity score was established: ‘‘0’’ reflected the lack of Dicer
immunoreactivity and was the most common pattern in normal
skin, carcinomas and sarcomas. Weakly positive (‘‘1’’) staining was
observed in epidermal keratinocytes and melanocytic nevi.
Moderately positive (‘‘2’’) staining was assigned to modest granular
staining. Strongly positive (‘‘3’’) staining consisted of diffuse and
homogenous staining. Basal levels of Dicer were detected in
epidermal keratinocytes. Only staining of tumor cells was scored in
comparison to adjacent keratinocytes (internal positive control).
Melanophages, specialized macrophages containing dark, brown
coarse melanin pigment were not scored. Two investigators scored
the stained slides independently. Scores for multiple cores from
one case were averaged, and final Dicer scores were categorized
into a three-level grouping of Negative, Low (.0 and #1.5) or
High (.1.6) for analyses that included all 404 patients. For the
exploratory analyses (n = 19), a dichotomous breakdown of
Negative or Positive (.0) Dicer expression was used. These
analyses included the following clinical and histopathological
variables: AJCC Stage (I, II, III, IV); Distant Metastases, Non-
Sentinel Node Metastases, Organ Metastases, Evidence of
Regression, and Ulceration, which were treated as dichotomous
variables; Melanoma Histology (Superficial Spreading, Nodular,
Acrolentiginous or Lentigo Maligna); Vital status (alive, dead);
and, Mitotic Index (mm2), Clark’s Level and Breslow’s depth of
invasion, i.e. Tumor Thickness (mm) were treated as continuous
variables. Pearson Chi-Square tests were employed to assess
categorical levels of Dicer status. Kruskal-Wallis (k = 3) or Mann-
Whitney (k = 2) non-parametric tests were used for analyses when
Dicer expression was treated as a continuous value as well as for
analyses of Mitotic Index, Clarks Level and Breslow’s depth of
invasion. SPSS version 18.0 was used, and tests were two-sided in
all analyses.
Bioinformatic Pooled Analysis on Gene Expression
Profiling
Using NextBio (nextbio.com), we mined and pooled publically
available gene expression profiling data interrogating the mRNA
levels of the genes encoding all of the known enzymes involved in
the canonical miRNA biogenesis and maturation pathway (Table
S1). This analysis included 25,135 genes profiled from 20 disease
groups consisting of 139 total excision specimens of cutaneous
melanoma in various stages (Clark level I and II-radial growth
phase, Clark level III, IV and V-vertical growth phase), melanoma
metastases to skin and lymph node, common acquired melanocytic
nevi, dysplastic nevi with low and high atypia, normal skin, basal
Dicer Expression in Melanoma
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cell carcinoma and squamous cell carcinoma. These two studies
used whole genome oligo-microarray platforms: GPL1708 Agi-
lent-012391 Whole Human Genome Oligo Microarray G4112A
[21] and GPL570 Affymetrix GeneChip Human Genome U133
Plus 2.0 Array [22]. This analysis examined the 5,023 genes (out of
25,135) significantly altered based on the following criteria: overall
gene score (top ranking genes), disease group score (significance
among disease groups) and P-value specific to the gene and the
disease group. For example, Dicer1 ranked among the top 20%
most significantly altered genes, appeared in 11 out of 20 disease
groups and it was expressed 2.54-fold higher than basal cell
carcinoma (P-value = 0.0055) (Table S1). Color specified direction
of regulation (red= up, green = down and orange = no direction),
while size indicates magnitude of change.
Cell Lines and Cell Culture
The detailed summary of cell lines is shown (Table S2). TE 354.T
cell line was purchased from the American Type Culture Collection
(Manassas, VA) and cultured in Dulbecco’s modified Eagle’s medium
with 10% fetal bovine serum (Gibco, Sydney, Australia) and 1%
penicillin/streptomycin (Invitrogen). A2058, A375P, C32, A375SM
and HEK 293 cells (embryonic kidney 293) were kindly provided by
Dr. Stanley N. Cohen, Stanford school of medicine, CA. These cells
were cultured in Dulbecco’s modified Eagle’s medium supplemented
with 10% FCS and 2 mM glutamine. WM983A (Coriell), WM278
(Coriell), WM35 and WM1552C were purchased (Wistar institute,
Philadelphia, PA) and cultured in 80% MCDB153 (Sigma), 20%
Leibovitz’s L15 (Mediutech), 2% fetal bovine serum, 5 ug/ml insulin
(Sigma) and 1.68 mM CaCl2. Three types of epidermal primary
melanocytes isolated from 3 individuals with light, medium and dark
skin were purchased from ScienCell (Carlsbad, CA) and cultured in
melanocyte medium as specified by ScienCell. All cell cultures, except
for TE 354.T (at 37uC and 10% CO2), were incubated at 37uC in a
5% CO2 completely humidified incubator.
Western Blot Detection of Dicer
Cultured cells were lysed in NP40 Cell Lysis Buffer (Invitrogen,
Carlsbad, CA) and spun at 16,0006g to extract soluble proteins.
Twenty microgram of total protein was resolved on a 4-20% Tris-
Glycine gradient gel (BioRad) and blotted onto a nitrocellulose
membrane. The membrane was blocked with 5% powdered
nonfat milk in TBST buffer for 1 hour, then incubated with 1:500
dilution of anti-Dicer or 1:50,000 dilution of anti-SDHA antibody
(Abcam) or 1:1000 dilution of a-tubulin antibody overnight at
4uC. The membrane was then washed three times with TBST
buffer and incubated with anti mouse HRP conjugated secondary
antibody, washed thrice with TBST, developed with the ECL
Western Blotting Substrate (Pierce, Rockford, IL) and imaged and
analyzed on a Kodak Image Station 4000 MM Pro (Carestream
Health, Rochester, NY). Relative band intensity for Dicer was
normalized against SDHA or a-tubulin as a loading control and
quantified according to pixel intensity using Adobe Photoshop.
Quantitative real-time reverse transcription-PCR (qRT-
PCR)
For measuring mRNA levels, total RNA was extracted from
cultured cells with TRIzol and the reverse transcription of purified
RNA was performed using oligo(dT) priming and superscript II
reverse transcription according to the manufacturer’s instructions
(Invitrogen). The quantification of Dicer and GAPDH transcripts
by Real-time quantitative PCR amplification of a cDNA template
corresponding to 15 ng total RNA was performed using TaqMan
Universal PCR Master Mix and TaqMan gene expressions assay
probes (Applied Biosystems, Foster City, CA, USA). As previously
described [13], for all miRNAs, 5 ng total RNA was used as a
template for TaqManH miRNA assays (Applied Biosystems, Foster
City, CA, USA). All reactions were run in an ABI 7500 Fast
system (Applied Biosystems). Cycle threshold (Ct) values for each
miRNA were normalized to a small nuclear RNA RNU6 and for
Dicer mRNA Ct values were normalized to GAPDH (DCt) and
represented as 22DCT.
Results
Dicer Up-regulation in Cutaneous Malignancies Is
Specific to Melanoma
We initially sought to determine if Dicer is expressed in any of
the major categories of human cutaneous malignancies, namely
Table 1. Dicer expression in relation to tumor type (n = 404).
Dicer Immunoreactivity
Negative Low (#1.5) High (.1.6) P-Value1 Mean ± SD P-Value
Total n % n % n %
Tumor Type Normal Tissue 12 11 91.7% 1 8.3% 0 - 0.0460.14
Melanocytic Nevus 71 13 18.3% 48 67.6% 10 14.1% 0.8360.60
Cutaneous Melanoma 95 18 18.9% 33 34.7% 44 46.4% 1.4060.96
Acrolentiginous Melanoma 40 4 10.0% 14 35.0% 22 55.0% 1.6160.92
Mucosal Melanoma 24 8 33.3% 13 54.2% 3 12.5% 0.7960.65
Ocular Melanoma 4 0 - 2 50.0% 2 50.0% 1.5060.58
Desmoplastic Melanoma 8 5 62.5% 2 25.0% 1 12.5% 0.4460.73
Metastatic Melanoma 52 2 3.8% 21 40.4% 29 55.8% 1.7160.83
Carcinoma 73 45 61.6% 24 32.9% 4 5.5% 0.3960.59
Sarcoma 12 11 91.7% 1 8.3% 0 - 0.0860.29
Neural Tumors 13 9 69.2% 4 30.8% 0 - ,0.0001 0.2360.39 ,0.00012
1Pearson Chi-Square test for proportions.
2Kruskal-Wallis (k = 3 or more) non-parametric test for continuous values.
doi:10.1371/journal.pone.0020494.t001
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melanoma, carcinoma or sarcoma. To this end, we tested a large
clinical sample set of formalin-fixed paraffin-embedded (FFPE)
benign and malignant tumors (n = 404) including melanocytic nevi
(benign melanocytic hyperplasia), a variety of melanoma subtypes
(cutaneous, acrolentiginous, mucosal, ocular and desmoplastic), a
variety of carcinomas (squamous, basal cell and eccrine) and
sarcomas (Table 1) using a monoclonal anti-human Dicer
antibody and immunohistochemistry on tissue microarrays
(TMAs) (Fig. 1A) and full tumor sections (Fig. S1A-F). After
determining the immunostaining pattern for Dicer in normal skin
and other organs, we established a semi-quantitative, four-point
ordinal immunoreactivity scoring scale: negative (0), weakly
positive (1), moderately positive (2) and strongly positive (3).
Scores for multiple cores from one case were averaged, and final
Dicer scores were categorized into a three-level grouping of
Negative, Low (.0 and #1.5) or High (.1.6) for analyses that
included all 404 patients (Table 1). In normal skin, epidermal
keratinocytes expressed Dicer consistently at low levels (Fig. 1B).
Carcinoma cells of skin (basal and squamous), adenocarcinoma
cells (primary or metastatic) and sarcoma cells expressed none to
very low levels of Dicer (Fig. 1C-E). In contrast, the cytoplasm of
primary cutaneous and metastatic melanoma cells exhibited high
levels of Dicer immunoreactivity (Fig. 1F-G). The majority of
carcinomas (94.5%), sarcomas (100%) and tumors with neural
differentiation (100%) of the skin was negative for Dicer or
expressed it at low levels (Table 1). Among tumors with
melanocytic differentiation, we observed low levels of Dicer
immunoreactivity in the cytoplasm of melanocytic nevus cell
Figure 1. Dicer was specifically expressed in melanoma cells and not carcinoma or sarcoma cells. A) Dicer immunoreactivity was variable
across different types of skin cancer by immunohistochemistry using tissue microarrays. B) Normal epidermal keratinocytes exhibited low, basal level
of Dicer expression. C–E) The cytoplasm of basal cell carcinoma, squamous cell carcinoma and sarcoma cells were negative for Dicer, respectively. In
contrast, melanoma cells strongly and diffusely expressed Dicer in both primary cutaneous (F) and metastatic (G) melanoma. Original magnification:
A, 20X; B–C, 100X and D–G, 200X.
doi:10.1371/journal.pone.0020494.g001
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(Fig. 2A) compared to the high levels seen in cutaneous and
acrolentiginous melanomas (Fig. 2B-E). The cytoplasm of mucosal
melanoma cells was devoid of Dicer immunoreactivity (Fig. 2F).
Dicer was consistently expressed at high levels in the majority of
metastatic (55.8%), acrolentiginous (55.0%) and cutaneous
(46.4%) melanomas compared to mucosal melanoma (12.5%),
conferring further cancer-cell specificity among different types of
melanomas (Table 1). The remainder of Dicer-positive cutaneous
melanomas expressed Dicer either at low levels (34.7%) or
exhibited no expression (18.9%). Two different patients with
cutaneous melanoma (both excised from the thigh) exemplified
this variability in expression Dicer. The melanoma from patient 1
expressed Dicer at low levels (Fig. 2B and C) compared to that in
patient 2 who expressed Dicer at high levels (Fig. 2B and D). Dicer
expression was not associated with differences in gender (n = 328)
or age (n = 335) in the examined cutaneous tumors (Table S3).
Among the cutaneous (n = 93) and acrolentiginous (n = 40)
melanomas examined, there was no statistically significant
association between Dicer expression and the anatomic site (head
and neck, trunk, upper and lower extremities or genital skin)
(Table S4).
Overall, when compared among all examined cutaneous
malignancies, Dicer up-regulation was tumor-type specific by
immunostaining, as Dicer was highly expressed by melanomas
(metastatic and cutaneous) compared to carcinomas or sarcomas
(P,0.0001, Fig. 3A). Furthermore Dicer up-regulation was specific
to the melanoma subtype, i.e. cutaneous and acrolentiginous
compared to mucosal and desmoplastic melanomas (P,0.0001,
Fig. 3B). Importantly, higher Dicer levels were detected in
cutaneous, acrolentiginous and metastatic melanomas compared
to common melanocytic nevi. To confirm the up-regulation of
Dicer in melanoma, we performed a pooled analysis by mining
published whole genome oligo-microarray dataset on two recent
large studies that profiled gene expression pattern in excisional
specimens of cutaneous tumors (n = 139) [21,22]. The combined
dataset included 20 different disease groups consisting of
Figure 2. Dicer was expressed at higher levels in cutaneous and acrolentiginous melanomas. A) Intradermal melanocytic nevus cells
weakly expressed Dicer in a small group of cells in the superficial dermis (arrowheads) whereas melanoma cells diffusely expressed Dicer at higher
levels (B). However, two independent individuals with cutaneous melanoma (CM), both excised from the thigh, expressed Dicer at different levels (B,
left and right cores). C–D) Both tissue cores are shown at a higher magnification (CM, thigh-1 and CM, thigh-2). The immunoreactivity for Dicer in
melanoma cells was granular and cytoplasmic. E) Cancer cells strongly expressed Dicer in an acrolentiginous melanoma while they were negative for
Dicer in a mucosal melanoma (F). Original magnification: A–B, 100X; C, E–F, 200X and D, 400X.
doi:10.1371/journal.pone.0020494.g002
Dicer Expression in Melanoma
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20494
Dicer Expression in Melanoma
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20494
cutaneous melanoma in various stages (in situ, Clark level I and II-
radial growth phase, Clark level III, IV and V-vertical growth
phase), melanoma metastases to skin and lymph node, common
acquired melanocytic nevi, dysplastic nevi with low and high
atypia, normal skin, basal cell carcinoma and squamous cell
carcinoma (Table 2). The combined dataset provided 25,135
genes, which we interrogated for Dicer mRNA expression levels.
Comparing cutaneous melanoma to other skin cancers, squamous
and basal cell carcinoma, or normal skin (mostly consisting of
keratinocytes) showed significantly higher levels Dicer mRNA in
melanoma (Fig. 3C, Table 2), confirming our immunostaining
results (Fig. 3A) and indicating an up-regulation at the level of
mRNA accumulation. Furthermore, invasive and metastatic
melanomas had significantly higher levels of Dicer mRNA than
common melanocytic nevi (Fig. 3C, Table 2), again confirming
our immunostaining results (Fig. 3B). Interestingly, the Dicer
mRNA levels are decreased in dysplastic when compared common
melanocytic nevi and in melanoma in situ when compared to
invasive (Fig. 3C, Table 2). Overall, these results showed that
Dicer up-regulation, at both the protein and the RNA levels, is
specific to melanoma subtypes and that Dicer levels are higher in
primary cutaneous and metastatic melanomas compared to
common melanocytic nevi.
Clinical Features Associated with Dicer Up-regulation
To characterize Dicer expression pattern and distribution, we
immunostained melanocytic nevi, cutaneous and metastatic
melanomas in complete sections (n = 33). In 30% of cutaneous
melanomas, the intratumoral expression of Dicer varied where
immunoreactivity was focally high compared no expression in
other areas within the same lesion (Fig. S1A). Dicer was expressed
both in the intraepidermal (in-situ) and dermal (invasive) melanoma
cells (Fig. S1B-D). The majority of cutaneous melanomas, TMAs
and complete sections, expressed Dicer either at high (44 of 95,
46.3%) or low (33 of 95, 34.7%) levels; however a minority of the
cases (18 of 95, 18.9%) was negative for expression. This finding
prompted us to investigate whether this difference might be
associated with clinical outcome in cutaneous melanomas patients
with available clinical information. For 19 patients, tumor
pathological features, clinical stage and clinical follow-up (rage
7.1 to 69.7 months; median= 22.4 months; mean= 26.6 months)
were available. Dicer expression level was significantly associated
with tumor mitotic index (P=0.04, n = 19) and Breslow’s depth of
invasion (P=0.03, n = 19) (Fig. 4A-B-D, Tables 3-4), two of three
most important parameters currently used in staging and
predicting prognosis for melanoma patients by the American
Joint Committee on Cancer (AJCC) [19]. Dicer expression was not
significantly associated with other tumor pathological features such
as histological subtype, inflammation (tumor infiltrating lympho-
cytes), regression, ulceration or Clark’s level (Table 4). Most
important, Dicer expression significantly correlated with metasta-
sis to the non-sentinel lymph node (SLN, P=0.04, n= 16) (Fig. 4C,
Table 4) and the AJCC clinical stage (P=0.009, n= 19) (Fig. 4D).
Melanoma patients with positive Dicer expression did demonstrate
a trend towards higher rates of SLN, organ and distant metastases
(Table 4); however this association did not reach a statistical
significance.
Figure 3. Dicer expression was cancer-cell specific among cutaneous malignancies and was significantly higher in primary and
metastatic melanoma compared to common melanocytic nevus. A) Primary cutaneous (n = 95) and metastatic (n = 52) melanomas had the
highest levels of Dicer immunoreactivity vs. carcinomas (n = 73) and sarcomas (n = 12). B) Cutaneous (n = 95) and acrolentiginous (n = 40) melanomas
had the highest levels of Dicer immunoreactivity vs. melanocytic nevi (n = 71), mucosal (n = 24) and desmoplastic (n = 8) melanomas. Dicer
immunoreactivity is shown as mean (boxed)62 standard error (SE). The statistical significance was measured for all independent samples comparing
to each other (Kruskal-Wallis Test, P,0.0001). C) Pooled analysis performed on publically available transcriptional profiling data showed significant
changes in Dicer mRNA levels during melanoma progression. This analysis included 25,135 genes from 20 disease groups and 139 individual
specimens of squamous cell carcinoma (SCC), basal cell carcinoma (BCC), primary melanoma (PM), common nevus (CN), dysplastic nevus with low
(DNL), dysplastic nevus with high atypia (DNH), primary melanoma vertical growth phase (PM VGP), melanoma in situ (MIS), lymph node melanoma
metastases (LNMM), dermal melanoma metastases (DMM), normal skin (NS) and melanoma metastases (MM) [21,22]. Dicer1 ranked among the top
20% most significantly altered genes.
doi:10.1371/journal.pone.0020494.g003
Table 2. Pooled analysis performed on Dicer mRNA
expression in publically available gene expression profiling
studies (clinical sample size = 139, disease groups = 20).
DICER1
P-value Fold change
NS vs. BCC NS NS
NS vs. SCC NS NS
SCC vs. BCC NS NS
SCC vs. PM 0.0108 +2.39
BCC vs. PM 0.0055 +2.54
CN vs. DNL 0.0006 22.17
CN vs. DNH 0.0074 21.49
CN vs. C I RGP NS NS
CN vs. C II RGP NS NS
CN vs. C III VGP NS NS
CN vs. C IV VGP NS NS
CN vs. C V VGP 0.0323 +2.21
MIS vs. PM 0.0391 23.25
CN vs. LNMM 0.0244 +2.95
CN vs. DMM 0.0242 +1.85
NS vs. MIS NS NS
NS vs. PM 0.0082 +2.36
NS vs. MM 0.0045 +2.42
MIS vs. MM 1.70E-06 +2.04
PM vs. MM NS NS
To stay consistent with the direction of disease progression, the sign (+ or 2)
was changed appropriately. Fold changes with a (2) sign are lower and those
with a (+) sign are higher than the disease group to which it was compared. For
example, PM showed 2.36-fold increase in Dicer mRNA levels when compared
to NS. The abbreviations of disease groups are as follows: DNL-dysplastic nevus
low-grade atypia; DNH-dysplastic nevus high-grade atypia; CN-common nevus;
C I RGP-Clark’s level I radial growth phase; C II RGP-Clark’s level II radial growth
phase; C III VGP-Clark’s level III vertical growth phase; C IV VGP-Clark’s level IV
vertical growth phase; C V VGP-Clark’s level V vertical growth phase; LNMM-
lymph node metastatic melanoma; DMM-dermal metastatic melanoma; MIS-
melanoma in situ; PM-primary melanoma invasive; MM-metastatic melanoma;
NS-normal skin; BCC-basal cell carcinoma; SCC-squamous cell carcinoma. NS-
not significant.
doi:10.1371/journal.pone.0020494.t002
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Expression of Dicer and let-7 miRNA family in vitro
Our findings in clinical melanoma specimens raised the
question of whether Dicer up-regulation might be intrinsic to
the tumor cells. We compared Dicer protein levels between
primary melanocytes, primary (n = 3) and metastatic (n = 3)
melanoma cell lines. Western blot analysis combined with
measured relative band intensity, normalized against succinate
dehydrogenase (SDHA), showed .2 to 4-fold higher Dicer levels
in melanoma cell lines (WM278, WM1552C and A375P) when
compared to melanocyte-L or other melanoma cell lines (WM35
and A375M) (Fig. 5A-B). Furthermore, we tested additional cell
lines; combined western blot analysis and measured relative band
intensity showed .2-fold higher Dicer levels in melanoma cell
lines (WM1552C and A2058) compared to basal cell carcinoma
(BCC), primary melanocytes (n = 3) or other melanoma cell lines
(WM35 and C32) (results not shown). The melanocytes were
derived from three different individuals with light, medium and
dark skin color. Dicer levels were comparable among the three
melanocytes, despite the skin color. Overall, Dicer expression in
cell lines recapitulated the observed deregulation in clinical
specimens, confirming higher Dicer immunostaining in melano-
mas when compared to melanocytic nevi or carcinomas of the skin
(Figs. 1, 2 and 3).
Given the differential levels of Dicer expression in melanoma
cell lines and the prior finding of let-7a miRNA exerting a negative
feedback loop on Dicer expression in lung and pancreatic cell lines
[23], it was conceivable that the differences in let-7a miRNA levels
might be associated with Dicer regulation via such mechanism in
melanoma. We compared the relative expression of the entire let-7
family to Dicer mRNA levels using quantitative real-time reverse
transcription-PCR (qRT-PCR). Neither Dicer mRNA nor Dicer
protein levels correlated with any of the mature miRNAs tested
(let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, left-7g or let-7i).
Interestingly, we found that let-7b expression levels are signifi-
cantly down-regulated in metastatic (A375P, A375SM and A2058)
compared to primary (WM35, WM1552C and C32) melanoma
Figure 4. Dicer expression significantly correlated with clinical outcome in patients with cutaneous melanoma. A–B) The mean values
for melanoma mitotic index (per mm2) and Breslow’s depth of invasion significantly correlated with Dicer expression (P= 0.04 and P= 0.03,
respectively). C) Dicer immunoreactivity score was significantly associated with metastasis to non-sentinel lymph node (SLN) in patients with
cutaneous melanoma (P= 0.04). D) The American Joint Commission on Cancer (AJCC) staging was significantly associated with Dicer expression
(P=0.009).
doi:10.1371/journal.pone.0020494.g004
Table 3. Dicer expression in relation to melanoma mitotic
activity and depth of invasion (n = 19).
Dicer Immunoreactivity
Negative n=5 Positive n=14 P-Value1
Mean 6 SD Mean 6 SD




Clark’s Level 3.2060.84 3.7960.43 0.08
1Mann-Whitney (k = 2) non-parametric test for continuous values.
doi:10.1371/journal.pone.0020494.t003
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cell lines; while let-7d levels are significantly down-regulated in all
six melanoma cell lines (metastatic and primary) compared to
primary melanocytes (Fig. S2).
Perturbed miRNA Biogenesis Pathway during Melanoma
Progression
Since the expression of Dicer is significantly altered from
common to dysplastic nevi to melanoma in situ to invasive and to
metastatic melanoma, we interrogated the same combined
dataset, which included 20 different disease groups and 25, 135
genes, for the mRNA levels of all the known enzymes involved in
canonical miRNA biogenesis by performing a pooled analysis
mining published whole genome oligo-microarray dataset
[21,22]. Enzymes tested in the canonical miRNA biogenesis
pathway included Drosha, DGCR8, RAN, XPO5, Dicer1,
GEMIN3, GEMIN4, EIF2C2, Ago2 and TRBP (Table S1).
Dicer1, DGCR8 and Gemin4 ranked among the top ,20
percentile of most significantly altered genes. We represent this
data with respect to a linear, step-wise progression model for
melanomagenesis, plotting changes in the expression level of the
enzyme detected in our own immunostaining (protein) and in
microarray pooled analysis (mRNA) (Fig. 6). This analysis
suggests that the biogenesis of mature miRNAome maybe
enhanced in the early steps of melanocyte transformation and
melanoma formation raising the possibility that Dicer may play a
central role in the melanocyte transformation and metastasis.
Surprisingly, Dicer, Drosha and Gemin4 are down-regulated in
melanoma in situ compared to invasive melanoma; in addition,
Dicer is down-regulated in dysplastic nevi compared to common
nevi, suggesting a global repression of miRNA biogenesis in these
steps.
Discussion
In this study, we examined the expression and the clinical
relevance of Dicer in cutaneous melanoma. We showed that a
large portion of cutaneous melanomas exhibited up-regulation of
Dicer significantly associated with aggressive cancer features. We
demonstrated definitive evidence that Dicer up-regulation is
specific to the malignant proliferation of melanocytes (melanoma)
and not keratinocytes (carcinoma) or fibroblasts (sarcoma) in 404
human skin tumors. Given that the ‘‘melanoma disease group’’ is a
heterogeneous cancer, to have a complete representation, we
compared Dicer expression among the various subtypes of
melanomas occurring in glabrous (subungual, palm and sole) skin,
non-glabrous skin, eye, mucosal sites (e.g. oral, urothelial and anal
mucosa) and metastatic sites (variety of organs) to melanocytic
Table 4. Dicer expression in relation to melanoma clinicopathological features (n = 19).
Dicer Immunoreactivity
Negative Positive P-Value1 Mean ± SD P-Value
n % n %
Subtype Superficial
spreading
5 29.4% 12 70.6% 1.3560.99
Nodular 0 - 2 100% 0.99 2.0061.41 0.432
Tumor infiltrating lymphocytes Absent 2 28.6% 5 71.4% 1.4361.13
Present 3 25.0% 9 75.0% 0.99 1.4160.99 0.962
Regression Absent 4 25.0% 12 66.7% 1.5061.03
Present 1 50.0% 1 50.0% 0.49 0.5060.71 0.182
Ulceration Absent 5 38.5% 8 61.5% 1.2361.09
Present 0 - 6 100% 0.13 1.8360.75 0.282
Stage I 5 71.4% 2 28.6% 0.7161.25
II 0 - 4 100% 1.7560.50
III 0 - 2 100% 1.5060.71
IV 0 - 6 100% 0.009 2.0060.63 0.173
Sentinel Lymph Node Metastases Negative 5 38.5 8 61.5% 1.2361.09
Positive 0 - 6 100% 0.12 1.8360.75 0.282
Non-Sentinel Node Metastases4 Negative 5 45.5% 6 54.5% 1.0061.10
Positive 0 - 5 100% 0.12 2.2060.45 0.042
Organ Metastases Absent 5 33.3% 10 66.7% 1.3361.11
Present 0 - 4 100% 0.53 1.7560.50 0.522
Distant Metastases M0 5 38.5% 8 61.5% 1.1561.07
M1 0 - 6 100% 0.13 2.0061.41 0.102
Vital Status Alive 0 - 4 100% 1.7560.50
Dead 5 33.3% 10 66.7% 0.53 1.3361.11 0.522
1Pearson Chi-Square test for Stage and Tumor Thickness (Table 3); Fisher’s Exact Test for all other variables.
2Mann-Whitney (k = 2) non-parametric test for continuous values.
3Kruskal-Wallis (k = 3 or more) non-parametric test for continuous values.
4Three cases with unknown nodal status.
doi:10.1371/journal.pone.0020494.t004
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nevi. These immunostaining results clearly showed that Dicer up-
regulation was specific to cutaneous, acrolentiginous and meta-
static melanomas. To complement the immunostaining, we
carried out a pooled analysis using two recent large studies that
profiled gene expression pattern in cutaneous tumors. This
analysis corroborated our immunostaining data and indicated
that at least a component of Dicer up-regulation in melanoma is
due to differences in mRNA accumulation.
Figure 5. Dicer expression in cell lines recapitulated the
observed deregulation in clinical specimens. A) Western blot
analysis of Dicer shows a 219-kDa band. Relative band intensity was
compared to succinate dehydrogenase (SDHA, 68 kDa) as a loading
control. B) Western blot quantification showed .2 to 4-fold change in
Dicer levels in melanoma cell lines (WM278, WM1552C and A375P)
when compared to melanocyte-L or other melanoma cell lines (WM35
and A375M). C) Dicer mRNA expression did not correlate with mature
let-7a expression in vitro. Using qRT-PCR, the relative expression levels
of let-7a miRNA and Dicer mRNA were compared to show no significant
correlation. All qRT-PCRs were performed in triplicates. Data were
normalized to small nuclear RNA RNU6 for let-7a and GAPDH mRNA for
Dicer. The samples are: Primary melanocytes were cultured from
individuals with light (Melanocyte-L), medium (Melanocyte-M) and dark
(Melanocyte-D) skin color, WM983A (primary melanoma), WM278
(primary melanoma), WM35 (primary melanoma), WM1552C (primary
melanoma), C32 (amelanotic primary melanoma), A375P (metastatic
melanoma), A375SM (metastatic melanoma) and A2058 (metastatic
melanoma).
doi:10.1371/journal.pone.0020494.g005
Figure 6. Enzymes involved in the canonical miRNA biogenesis
are deregulated during melanoma progression. Combined Dicer
immunoreactivity, presented herein (denoted by asterisk ‘*’), and mRNA
transcriptional profiling [21,22] examined for Dicer and other enzymes
in the miRNA biogenesis showed a global change in their expression
levels during tumor progression. Enzymes shown in red are up-
regulated and those in green are down-regulated. Up-regulation of
Dicer (italicized) from common melanocytic nevus to invasive
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Although our results provide strong evidence that up-regulated
Dicer was tumor-cell specific and reflective of mRNA levels, these
results provided little mechanistic explanation. Given the involve-
ment of Dicer, Dicer products, and associated components of the
RNAi machinery in diverse cellular processes [24] there are
certainly numerous mechanisms both for the potential regulation
of Dicer in melanoma and for the effects of this regulation in the
context of the tumor. Further analysis of both questions will
certainly be warranted. Here, we provide a number of (not
necessarily exclusive) connections between Dicer functions and
other factors that may regulate or depend on these.
First, the presence of cell-specific transcription factors might be
expected to partially explain the difference in Dicer expression
between melanocytes vs. keratinocytes or fibroblasts. Recently, it
has been shown that Dicer is a direct transcriptional target of
microphthalmia-associated transcription factor (MITF); tissue-
restricted master transcriptional regulator of melanocytes; and
that targeted KO of Dicer is lethal to melanocytes [25]. MITF
targeting Dicer in melanocytes may partially explain our findings
of up-regulated Dicer in melanoma and not carcinoma or
sarcoma. As for the underlying mechanisms of increased Dicer
expression in melanoma, one class of conceivable mechanisms
would occur if human Dicer were amplified through gains in DNA
copy number by genomic instability. Dicer is mapped to
chromosome 14 (14q32.13); a genetic locus altered in other
human malignancies: esophageal carcinoma [26], nasopharygeal
carcinoma [27] and urothelial carcinoma [28]. From a set of
primary melanoma cell lines, Dicer1 locus showed 19.6% gain and
8.7% loss of DNA copy number [29]. Finally, it has been
demonstrated that let-7a enforces a negative feedback loop on
Dicer expression in lung and pancreatic carcinoma cell lines [23].
Despite the potential of this feedback loop, our measurements of
levels for let-7a (or other members of let-7 family) and Dicer do not
support a let-7 regulatory loop as the key element of Dicer up-
regulated expression in melanoma cell lines.
We found that the expression of Dicer was variable among
cutaneous melanomas (n = 95) where, the great majority (81%) of
cases expressed it while 19% of cases demonstrated an absence of
immunoreactivity. Postulating that this difference could be
clinically relevant, we examined correlations with other clinical
features, observing a statistically significant association between
Dicer expression and melanoma mitotic index and Breslow’s depth
of invasion, both indicative of a more aggressive cancer (these are
two of the three most important AJCC staging parameters)
currently used to determine prognosis for melanoma patients [19].
Dicer expression significantly correlated with non-SLN metastasis
and AJCC stage but not disease-specific survival. Given the small
patient population with available clinical follow-up information in
this study (n= 19), our findings need to be validated in larger
melanoma cohorts. Our results suggest analogy to prostate
adenocarcinoma where up-regulated Dicer correlated with
metastasis to regional lymph nodes and clinical stage [16].
Deregulation of Dicer, or other enzymes in the miRNA biogenesis
pathway, maybe a common central feature shared by several solid
cancers [16,17,18,30,31,32,33,34] to globally regulate the biogen-
esis of oncomirs. From our pooled analysis focusing on all known
enzymes that participate in the biogenesis and maturation of
canonical miRNAs, we also propose the possibility of a more
general phenomenon where several deregulated RNAi enzymes, in
addition to Dicer, may influence the various steps in melanoma
progression (Fig. 6).
Overall, our results show definitive up-regulation of Dicer in
cutaneous melanoma, compared to other skin cancer types, which
correlated with a more aggressive behavior. When confirmed by
independent studies in larger cohorts, increased Dicer expression
may serve as a clinically useful prognostic biomarker for cutaneous
melanoma patients. Beyond this, a combined understanding of
deregulated Dicer and its influence on the expression pattern of
mature miRNAs may lead to indications of directions in which
small RNA modulations may contribute therapeutically in
melanoma treatment. During the revision of this manuscript, we
noted an abstract for a small pilot study [35] comparing Dicer
immunostaining pattern among cutaneous melanomas, melano-
cytic nevi and dysplastic nevi. The abstract suggested that a
significantly higher Dicer immunostaining was detected in
melanoma cells than in nevus cells.
Supporting Information
Figure S1 Expression of Dicer in primary cutaneous and
metastatic melanomas by immunohistochemistry using complete
tumor sections. A) Cancer cells focally expressed Dicer at high
levels in the left margin (arrowhead) compared to the cancer cells
in the center (asterisks) that were negative for Dicer in the same
cutaneous melanoma (CM). B) In another CM, cancer cells
expressed Dicer along the dermal-epidermal junction and
follicular epithelium (in situ, arrowhead) as well as in the dermis
(invasive, arrow). C) In an ulcerated CM, cancer cells, invading
throughout the dermis, strongly and diffusely expressed Dicer. D)
Cancer cells expressed Dicer in in situ and invasive components of
another CM. E) Melanoma cells expressed Dicer in a subcapsular
(arrowhead) location in the sentinel lymph node (SLN) of a patient
with metastatic melanoma (MM) compared to the adjacent nodal
tissue containing mature lymphocytes (asterisk) that are negative
for Dicer. F) In another patient with MM, cancer cells strongly
and diffusely expressed Dicer in the SLN, where expanding tumor
nodules obliterated the normal lymph node architecture. Under
higher magnification, Dicer was localized to the cytoplasm of
melanoma cells with a granular quality (inset D and F). Original
magnification: A, 200X; B-D, 100X, E, 200X and F, 100X; insets:
400X.
(TIF)
Figure S2 Dicer mRNA expression did not correlate with the
expression of any mature miRNA members in the let-7 family in
vitro. Using qRT-PCR, the relative expression levels of let-7b, let-
7c, let-7d, let-7d, let-7f and let-7g miRNAs and Dicer mRNA were
compared to show no significant correlation. However, let-7b
expression is significantly down-regulated in all three metastatic
compared to three primary melanoma cell lines; whereas let-7d
expression is significantly down-regulated in all 6 metastatic and
primary melanoma cell lines compared to three melanocytes. All
qRT-PCRs were performed in triplicates. Data were normalized
to small nuclear RNA RNU6 for let-7 family and GAPDH mRNA
for Dicer.
(TIF)
Table S1 Pooled analysis performed on enzymes in miRNA
biogenesis pathway in publically available gene expression
profiling studies (clinical sample size = 139, disease groups = 20).
(DOCX)
Table S2 Summary of cell lines, source and type.
(DOCX)
melanoma was found both in our study and others [21,22]. Dicer,
DGCR8 and Gemin4 ranked among the top 20 percentile of most
significantly altered genes.
doi:10.1371/journal.pone.0020494.g006
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Table S3 Dicer expression in relation to cutaneous tumors, sex
(n = 328) and age (n = 335).
(DOCX)
Table S4 Dicer expression in relation to melanoma type and
anatomic site (n = 133).
(DOCX)
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